1. Home
  2. BCDA vs PPBT Comparison

BCDA vs PPBT Comparison

Compare BCDA & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • PPBT
  • Stock Information
  • Founded
  • BCDA N/A
  • PPBT 2010
  • Country
  • BCDA United States
  • PPBT Israel
  • Employees
  • BCDA N/A
  • PPBT N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • PPBT Biotechnology: Pharmaceutical Preparations
  • Sector
  • BCDA Health Care
  • PPBT Health Care
  • Exchange
  • BCDA Nasdaq
  • PPBT Nasdaq
  • Market Cap
  • BCDA 7.9M
  • PPBT 8.7M
  • IPO Year
  • BCDA N/A
  • PPBT N/A
  • Fundamental
  • Price
  • BCDA $2.45
  • PPBT $3.28
  • Analyst Decision
  • BCDA Strong Buy
  • PPBT Strong Buy
  • Analyst Count
  • BCDA 1
  • PPBT 2
  • Target Price
  • BCDA $25.00
  • PPBT $126.50
  • AVG Volume (30 Days)
  • BCDA 54.7K
  • PPBT 42.3K
  • Earning Date
  • BCDA 03-26-2025
  • PPBT 03-04-2025
  • Dividend Yield
  • BCDA N/A
  • PPBT N/A
  • EPS Growth
  • BCDA N/A
  • PPBT N/A
  • EPS
  • BCDA N/A
  • PPBT N/A
  • Revenue
  • BCDA $71,000.00
  • PPBT N/A
  • Revenue This Year
  • BCDA N/A
  • PPBT N/A
  • Revenue Next Year
  • BCDA N/A
  • PPBT N/A
  • P/E Ratio
  • BCDA N/A
  • PPBT N/A
  • Revenue Growth
  • BCDA N/A
  • PPBT N/A
  • 52 Week Low
  • BCDA $1.63
  • PPBT $2.00
  • 52 Week High
  • BCDA $8.85
  • PPBT $20.60
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 56.72
  • PPBT 41.82
  • Support Level
  • BCDA $2.12
  • PPBT $3.06
  • Resistance Level
  • BCDA $2.73
  • PPBT $3.33
  • Average True Range (ATR)
  • BCDA 0.22
  • PPBT 0.25
  • MACD
  • BCDA 0.03
  • PPBT -0.02
  • Stochastic Oscillator
  • BCDA 58.21
  • PPBT 27.16

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Share on Social Networks: